Skip to main content
Top
Published in: Internal and Emergency Medicine 4/2023

06-03-2023 | Angiography | CE - MEDICAL ILLUSTRATION

An undetectable source of recurrent gastrointestinal bleeding: hemosuccus pancreaticus

Authors: Raffaele Borriello, Roberta Massaro, Valeria Abbate, Antonio Gasbarrini

Published in: Internal and Emergency Medicine | Issue 4/2023

Login to get access

Excerpt

A 57-year-old man was referred to the Emergency Room of our medical center for an episode of melena and multiple episodes of rectorrhagia during the last 3 days associated with intermittent abdominal pain. The patient had a history of chronic lithiasic pancreatitis, arterial hypertension, psoriasis, and a localized renal cell carcinoma treated with nephrectomy in 2017. Due to his oncologic surveillance program, he had recently performed an abdominal RM which had shown a fluid collection upon the body of pancreas compatible with a pancreatic pseudocyst. Actually, this patient was already known to our hospital, as 1 year before he had performed repeated accesses to our emergency department for repeated episodes of rectorrhagia, melena, and anemization and was hospitalized multiple times. First, in the april of 2019, he underwent an esophagogastroduodenoscopy (EGDS), a pancolonoscopy with retrograde ileoscopy, a videocapsule endoscopy, and a push-and-pull enteroscopy, which resulted negative for every gastrointestinal source of bleeding, and was therefore discharged; after few months, he was hospitalized again two more times for the same symptomatology, so he underwent again several angiography-CT scans, repeated endoscopic exams and even a scintigraphy with marked red blood cells, but no active bleeding sources or cause of gastrointestinal were found. Thus, he was discharged with a diagnosis of occult hemorrhage and prescribed long-acting octreotide. Then the patient was lost at follow-up due to the COVID-19 pandemic. He had self-suspended the administration of the drug after 6 months from last discharge. …
Literature
1.
go back to reference Yu P, Gong J. Hemosuccus pancreaticus: A mini-review. Ann Med Surg (Lond). 2018;28:45–48. Yu P, Gong J. Hemosuccus pancreaticus: A mini-review. Ann Med Surg (Lond). 2018;28:45–48.
2.
go back to reference Mandaliya R, Krevsky B, Sankineni A et al. Hemosuccus pancreaticus: a mysterious cause of gastrointestinal bleeding. Gastroenterol Res. 2014;7(1):32–37. Mandaliya R, Krevsky B, Sankineni A et al. Hemosuccus pancreaticus: a mysterious cause of gastrointestinal bleeding. Gastroenterol Res. 2014;7(1):32–37.
3.
go back to reference Yashavanth HS, Jagtap N, Singh JR, et al. Hemosuccus pancreaticus: a systematic approach. J Gastroenterol Hepatol. 2021;36(8):2101–2106. Yashavanth HS, Jagtap N, Singh JR, et al. Hemosuccus pancreaticus: a systematic approach. J Gastroenterol Hepatol. 2021;36(8):2101–2106.
Metadata
Title
An undetectable source of recurrent gastrointestinal bleeding: hemosuccus pancreaticus
Authors
Raffaele Borriello
Roberta Massaro
Valeria Abbate
Antonio Gasbarrini
Publication date
06-03-2023
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 4/2023
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-023-03242-7

Other articles of this Issue 4/2023

Internal and Emergency Medicine 4/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine